Promising drug duo targets rare blood cancer progression
NCT ID NCT05074355
First seen Jan 10, 2026 · Last updated May 05, 2026 · Updated 15 times
Summary
This study tests whether combining two drugs, venetoclax and azacitidine, is safe and effective for people whose myeloproliferative neoplasm (MPN) has advanced to a more aggressive phase. About 40 participants will receive the combination therapy. The goal is to see if the treatment can bring the cancer back under control or into remission.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOPROLIFERATIVE NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, M5G 2M9, Canada
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.